🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Important announcement from ATTACC, ⁦⁦ACTIV4a⁩ and ⁦remap-cap⁩: Full-dose blood thinners decreased need for life support and improved outcomes in hospitalized COVID-19 patients news.umanitoba.ca/blood-thinners…

ACTIV4a Aaron Kornblith UCSF CHIPPER UCSF Bakar Computational Health Sciences Institute UCSF Health UCSF Surgery I’d say that the real forces of nature are ACTIV4a remap-cap @ATTACC_COVID and their tireless, dedicated, brilliant, amazing leadership. Grateful for the opportunity to learn from and work alongside all of you.

Early results of a worldwide trial, coordinated in part by researchers at Pitt, found that full doses of heparin, a blood thinner, were not only safe but also reduced the need for vital organ support, such as ventilation for COVID-19 patients. More here: bit.ly/3oemMDy

We are releasing the interim (final data coming and publication submission pending) data from our amazing mpRCT collaboration w/ @ATTACC_COVID remap-cap to aid in clinician decision making on anticoagulants for #COVID19: nhlbi-connects.org/documents/mpRC… NIH NHLBI Matthew D. Neal, MD

@ATTACC_COVID A brief thread on interpreting organ support-free days as an endpoint for RCTs including @ATTACC_COVID remap-cap ACTIV4a Visit the simulator linked here to explore how the endpoint is influenced by its various components bit.ly/3oFZ57j

Todd Neale @connors_md Erik Klok Was nice discussing thrombosis and antithrombotic Rx in #covid19 from the mpRCT between ACTIV4a @ATTACC_COVID remap-cap

In this free access The BMJ editorial we discuss - the changing views & practice of thromboprophylaxis in hospitalised patients with COVI-19 through the pandemic - the recent RCT interim evidence from remap-cap @ATTACC_COVID & ACTIV4a as to what is the best dose of LMWH

Just had our ACTIV4a v1.1 protocol review - we hope to start randomizing to yes/no P2Y12i in hospitalized #COVID19 very soon!!@macky_neal Lucy Zumwinkle Kornblith, MD, FACS @ATTACC_COVID Mary Cushman 🫀🧠🩸 @PatrickLawlerMD @statberry

Final results of the mpRCT now on preprint server. In non-critically ill patients with COVID-19 (n=2219), therapeutic-dose anticoagulation with heparins increases survival to hospital discharge with reduced use of organ support. medrxiv.org/content/10.110…

For patients with #COVID19 receiving organ support in the ICU, #antiplatelet therapy with aspirin or P2Y12 inhibitor (which were found to be equivalent), was ineffective at improving death and organ support free days when compared to no #antiplatelet therapy. 1/8

Ryan Zarychanski SCCM ASH U of M Rady Faculty CCCTG Thrombosis Canada INVENT-VTE Looking forward to discussing these results next week. This will impact COVID-19 practice worldwide 🌐 @ATTACC_COVID remap-cap ACTIV4a Charlotte Summers Ewan Goligher @PatrickLawlerMD

Big night tomorrow night! Free livestream from 20:30 UTC criticalcarereviews.com Supported by @MyIntensiveCare

The final presentation timed with a public report. Come find out how the trial was done & what the role of therapeutic anticoagulation is in hospitalized patients with COVID-19. @ATTACC_COVID remap-cap ACTIV4a U of M Rady Faculty University Health Network CCCTG CanVECTOR Network ASH Justin Trudeau

Great international collaboration remap-cap @ATTACC_COVID ACTIV4a

Results of our therapeutic anticoagulation mpRCT with ACTIV4a and remap-cap is being live-streamed below. Results have now been published in the NEJM Moderate state: bit.ly/3ioKptb Critically ill: bit.ly/3lxzn7c Editorial: bit.ly/3ltYnMj

The incredible efforts of so many have led to the publication of both #mpRCT papers reporting results of anticoagulation in #COVID19. NEJM @ATTACC_COVID remap-cap ACTIV4a Most challenging/rewarding effort of my career nejm.org/doi/full/10.10… nejm.org/doi/full/10.10…

In noncritically ill patients with #COVID19, anticoagulation increased the probability of survival to hospital discharge without organ support. nej.md/3jrrxJx #IDTwitter

Superb Department of Medicine University of Toronto Grand Rounds by Ewan Goligher & @PatrickLawlerMD on the background, statistical approach & interpretation of the adaptive Bayesian design multiplatform @ATTACC_COVID / ACTIV4a / remap-cap anticoag in COVID trial. nejm.org/doi/full/10.10… nejm.org/doi/full/10.10…

#AHA21 #LBCT P2y12 Inhibitors in Noncritically Ill Hospitalized Pts With #Covid_19 #ACTIV4A 🩸thrombosis/inflam in #COVID 🩸RCT of P2Yy12, non-critical pt: 562 pts 🩸Stopped for futility; 40% women; Ticag used in 63% 🩸 No benefit of P2Yy12 in non-critical pts AHAMeetings

>95% confidence in futility in non-critically #Covid_19 - ACTIV4a still enrolling P2Y12 in critically ill patients - generating data at warp speed thanks to NIH Funding NIH NHLBI